STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress
Data demonstrates pharmacological inhibition of METTL1 inhibits…
Researchers aim to advance quantum sensing to transform disease diagnosis and prevention
With its unprecedented precision, quantum sensing holds the potential…
Calliditas Year-end report, January – December 2023
OCTOBER – DECEMBER 2023(COMPARED TO OCTOBER – DECEMBER 2022)
…
Rejuvenate Biomed’s clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia
Cutting-edge therapy shows meaningful improvements in muscle…
Poolbeg Pharma plc – Board Role Change and Launch of Employee Performance Incentive Plan
15 February 2024 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…
DelSiTech and Tolmar Announce Global License and Development Agreement
Tolmar secures global license to DelSiTech’s Silica Matrix…
Poolbeg Pharma plc – Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Former Amryt team's arrival supports increasing focus upon Rare…
Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline
Co-founded by world leading dermatology experts and Medicxi
…
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
C21 is a potentially transformative therapy for the treatment…
Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
First patients treated with H-Guard® at the National Institute…
Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
BLADE-VG2 trial will evaluate the safety and efficacy of…
Novo Holdings invests in Manipal Hospitals, a leading private hospital chain in India
COPENHAGEN and SINGAPORE, February 6 – Novo Holdings today…
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria,…
Update on Regulatory Review of leriglitazone in the EU
A re-examination for cerebral adrenoleukodystrophy (cALD) will…
Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
Investigating potential for an oral treatment in diabetic…
Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease
Copenhagen, Denmark, 23rd January 2024 – Vesper Bio ApS (“Vesper”…
Novo Holdings announces pre-IPO investment in Medi Assist, the top health benefits’ administrator in India
COPENHAGEN and SINGAPORE. Novo Holdings today announced its…
Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510
Synendos Therapeutics transitions to a clinical-stage biotech…
Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Market opportunity estimated to be greater than US$1 billion
Key…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York